Nallasivam Palanisamy MPhil

List of Publications by Year
in descending order

204	17,206	18436 62	14156 128
papers	citations	h-index	g-index

224	224	224	25079
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Noncoding Variant Near PPP1R3B Promotes Liver Glycogen Storage and MetS, but Protects Against Myocardial Infarction. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 372-387.	1.8	12
2	High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival. European Urology Open Science, 2021, 23, 1-8.	0.2	7
3	Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers. Clinical Cancer Research, 2021, 27, 2494-2504.	3.2	44
4	Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry. Cancers, 2021, 13, 2363.	1.7	1
5	Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease. European Urology Open Science, 2021, 29, 93-101.	0.2	5
6	Transcriptional network involving ERG and AR orchestrates Distal-lessÂhomeobox-1 mediated prostate cancer progression. Nature Communications, 2021, 12, 5325.	5.8	23
7	Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on wholeâ€mount radical prostatectomy tissue. Prostate, 2020, 80, 38-50.	1.2	15
8	A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q and 17q and a novel NTRK3â€SCAPER gene fusion. Journal of Cutaneous Pathology, 2020, 47, 70-75.	0.7	9
9	Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma With Features Mimicking Spindle Cell Lipoma. International Journal of Surgical Pathology, 2020, 28, 336-340.	0.4	6
10	High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients. Cancers, 2020, 12, 127.	1.7	60
11	Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. Modern Pathology, 2020, 33, 1092-1103.	2.9	18
12	A Novel COL1A1-CAMTA1 Rearrangement in Cranial Fasciitis. International Journal of Surgical Pathology, 2020, 28, 678-682.	0.4	3
13	Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. Modern Pathology, 2020, 33, 1791-1801.	2.9	6
14	Gene fusion characterisation of rare aggressive prostate cancer variantsâ€”adenosquamous carcinoma, pleomorphic giantâ€cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology, 2020, 77, 890-899.	1.6	15
15	The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clinical Cancer Research, 2020, 26, 4933-4946.	3.2	53
16	Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nature Communications, 2020, 11, 384.	5.8	56
17	Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1701-1709.	1.2	3
18	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. Oncogene, 2020, 39, 4077-4091.	2.6	19

#	Article	IF	Citations
19	Abstract 2012: Recurrent rearrangements of NAALADL2 in prostate, breast, cervical, head and neck and lung squamous cell carcinoma. , 2020, , .		2
20	Abstract B45: High-throughput label-free isolation and expansion of circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients for personalized treatments. , 2020, , .		0
21	Abstract A113: Comprehensive molecular mapping of prostate cancer- Approaching health disparities in molecular tumor heterogeneity perspective. , 2020, , .		0
22	Abstract 5302: Molecular subtype stratification for prostate cancer from mpMRI and histopathology images using convolutional neural networks and transfer learning. , 2020, , .		0
23	Epigenetic Silencing of miRNA-338-5p and miRNA-421 Drives SPINK1-Positive Prostate Cancer. Clinical Cancer Research, 2019, 25, 2755-2768.	3.2	48
24	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discovery, 2019, 9, 1538-1555.	7.7	88
25	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. Neoplasia, 2019, 21, 989-1002.	2.3	15
26	Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1): a target for cancer therapeutic intervention?. Cancer Cell International, 2019, 19, 224.	1.8	23
27	Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1751-1759.	1.2	8
28	Prostate cancer with comedonecrosis is frequently, but not exclusively, intraductal carcinoma: a need for reappraisal of grading criteria. Histopathology, 2019, 74, 1081-1087.	1.6	24
29	A Hierarchical Machine Learning Model to Discover Gleason Grade-Specific Biomarkers in Prostate Cancer. Diagnostics, 2019, 9, 219.	1.3	21
30	Introduction to Microarray Technology. , 2019, , 75-85.		2
31	Neurofilament is superior to cytokeratin 20 in supporting cutaneous origin for neuroendocrine carcinoma. Histopathology, 2019, 74, 504-513.	1.6	27
32	MP09-20â€ƒTHE DISTRIBUTION OF COMEDONECROSIS IN INTRADUCTAL VERSUS INVASIVE PROSTATE CANCER: ANALYSIS FROM A LARGE SINGLE CENTER PROSTATECTOMY SERIES. Journal of Urology, 2019, 201, .	0.2	0
33	Abstract 1332: High Throughput isolation and expansion of circulating tumor cells (CTCs) from Non-small cell lung cancer (NSCLC) patients for personalized treatments. , 2019, , .		1
34	Abstract 5225: Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. , 2019, , .		0
35	Abstract 4385: Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1): A target for cancer therapeutic intervention. , 2019, , .		0
36	Abstract 915: Pseudogene-associated recurrent gene fusion in prostate cancer. , 2019, , .		0

#	Article	IF	Citations
37	Abstract 4693: Evaluation of prostate tumor molecular heterogeneity using whole mount radical prostatectomy by dual immunohistochemistry and dual RNAin situhybridization. , 2019, , .		0
38	Abstract 4688: Evaluation of tumor heterogeneity in prostate biopsy samples. , 2019, , .		0
39	Abstract B016: CDK7 inhibition suppresses AR addicted Castration-Resistant Prostate Cancer through MED1 inactivation. , 2019, , .		0
40	Abstract C128: Reprogramming transcription factors SOX2 and REST modulates SPINK1 expression in governing cellular plasticity in prostate cancer. , 2019, , .		1
41	Abstract B124: ERG mediated transcriptional regulation ofDLX1homeobox gene represents a novel mechanism underlying prostate cancer progression. , 2019, , .		0
42	Abstract 1332: High Throughput isolation and expansion of circulating tumor cells (CTCs) from Non-small cell lung cancer (NSCLC) patients for personalized treatments. , 2019, , .		0
43	Abstract 4385: Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1): A target for cancer therapeutic intervention. , 2019, , .		0
44	Abstract 4688: Evaluation of tumor heterogeneity in prostate biopsy samples. , 2019, , .		0
45	Abstract 4693: Evaluation of prostate tumor molecular heterogeneity using whole mount radical prostatectomy by dual immunohistochemistry and dual RNAin situhybridization. , 2019, , .		0
46	Abstract 5225: Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. , 2019, , .		0
47	Abstract 915: Pseudogene-associated recurrent gene fusion in prostate cancer. , 2019, , .		0
48	Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements. Histopathology, 2018, 73, 321-326.	1.6	14
49	Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Medical Oncology, 2018, 35, 152.	1.2	13
50	Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. Prostate, 2018, 78, 1311-1320.	1.2	25
51	Enrichment and mutation detection of circulating tumor cells from blood samples. Oncology Reports, 2018, 39, 2537-2544.	1.2	6
52	Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2117-2125.	1.2	19
53	Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene. American Journal of Surgical Pathology, 2017, 41, 287-298.	2.1	60
54	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay. Clinical Cancer Research, 2017, 23, 5622-5630.	3.2	31

#	Article	IF	Citations
55	Solitary Fibrous Tumors of the Head and Neck. American Journal of Surgical Pathology, 2017, 41, 1642-1656.	2.1	111
56	Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. Cancer Research, 2017, 77, 5194-5206.	0.4	139
57	Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database. Modern Pathology, 2017, 30, 1603-1612.	2.9	30
58	Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis. Human Pathology, 2017, 67, 78-84.	1.1	29
59	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Research, 2017, 77, 74-85.	0.4	137
60	Sclerosing TFEB -rearrangement renal cell carcinoma: a recurring histologic pattern. Human Pathology, 2017, 62, 175-179.	1.1	15
61	The utility of <scp>ETV</scp>1, <scp>ETV</scp>4 and <scp>ETV</scp>5 <scp>RNA </scp>inâ€situ hybridization in the diagnosis of <scp>CIC</scp>â€“<scp>DUX</scp> sarcomas. Histopathology, 2017, 70, 657-663.	1.6	32
62	Expanded Circulating Tumor Cells from a Patient with ALK- Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study. Journal of Thoracic Oncology, 2017, 12, 397-402.	0.5	37
63	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. Prostate, 2017, 77, 10-21.	1.2	37
64	Abstract 1763: A novel RNAin situhybridization approach highly sensitive for detection of Merkel cell polyomavirus. , 2017, , .		0
65	RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC. PLoS Genetics, 2016, 12, e1006306.	1.5	52
66	Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin. American Journal of Dermatopathology, 2016, 38, 744-750.	0.3	8
67	Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically lowâ€risk patient as defined by targeted sequencing. Head and Neck, 2016, 38, E1646-52.	0.9	31
68	Tunable Thermalâ€Sensitive Polymerâ€“Graphene Oxide Composite for Efficient Capture and Release of Viable Circulating Tumor Cells. Advanced Materials, 2016, 28, 4891-4897.	11.1	130
69	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. Cell Reports, 2016, 17, 2620-2631.	2.9	68
70	Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian Journal of Urology, 2016, 3, 240-253.	0.5	33
71	Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions. Human Pathology, 2016, 58, 152-160.	1.1	48
72	MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. Oncogene, 2016, 35, 6330-6340.	2.6	74

#	Article	IF	Citations
73	SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 235.e1-235.e10.	0.8	17
74	Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Modern Pathology, 2016, 29, 157-165.	2.9	31
75	Unraveling tumor heterogeneity in prostate cancer by combined immunohistochemistry and RNA in situ hybridization. Journal of Cytology & Histology, 2016, 07, .	0.1	0
76	Abstract PR07: The landscape of molecular aberrations in pediatric and young adult cancer patients undergoing clinical sequencing for disease management: Novel biological findings from the Peds-MiOncoSeq study. , 2016, , .		0
77	Abstract 2849: RNA-binding protein FXR1 negatively regulates senescence by destabilizing mRNA CDKN1A and stabilizing noncoding RNA telomerase RNA component. , 2016, , .		0
78	Abstract A03: Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research. , 2016, , .		0
79	A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall. Histology and Histopathology, 2016, 31, 223-30.	0.5	6
80	Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 364-373.	0.6	7
81	Molecular profiling of ETS and nonâ€ETS aberrations in prostate cancer patients from northern India. Prostate, 2015, 75, 1051-1062.	1.2	17
82	Role and regulation of coordinately expressedde novopurine biosynthetic enzymesPPATandPAICSin lung cancer. Oncotarget, 2015, 6, 23445-23461.	0.8	80
83	Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Hormones and Cancer, 2015, 6, 67-86.	4.9	7
84	Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses. Human Pathology, 2015, 46, 690-697.	1.1	25
85	Extensive Survey of STAT6 Expression in a Large Series of Mesenchymal Tumors. American Journal of Clinical Pathology, 2015, 143, 672-682.	0.4	168
86	Targeting the MLL complex in castration-resistant prostate cancer. Nature Medicine, 2015, 21, 344-352.	15.2	165
87	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA - Journal of the American Medical Association, 2015, 314, 913.	3.8	333
88	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Research, 2015, 75, 3720-3727.	0.4	276
89	Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial1Share senior authorship.. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 108.e5-108.e13.	0.8	3
90	Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. Oncotarget, 2015, 6, 14614-14624.	0.8	34

#	Article	IF	Citations
91	Abstract 1585: Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis. , 2015, , .		0
92	Abstract 1581: A study of pulmonary and peripheral vein blood as sources of circulating tumor cells in early lung cancer. , 2015, , .		0
93	Prostate cancer cellâ€“stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Science Translational Medicine, 2014, 6, 252ra122.	5.8	86
94	Clear Cell Melanoma: A Cutaneous Clear Cell Malignancy. Archives of Pathology and Laboratory Medicine, 2014, 138, 1328-1336.	1.2	22
95	Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing. Human Pathology: Case Reports, 2014, 1, 21-28.	0.2	10
96	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nature Communications, 2014, 5, 5893.	5.8	121
97	At the intersection of primary pulmonary myxoid sarcoma and pulmonary angiomatoid fibrous histiocytoma: observations from three new cases. Histopathology, 2014, 65, 144-146.	1.6	26
98	TRIP13 enhances DNA repair to promote treatment resistance in cancer. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 118, e183.	0.2	0
99	Small cell carcinoma in the parotid harboring Merkel cell polyomavirus. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 118, 703-712.	0.2	19
100	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature Communications, 2014, 5, 5383.	5.8	522
101	Novel RNA Hybridization Method for the In Situ Detection of ETV1, ETV4, and ETV5 Gene Fusions in Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, e32-e40.	0.6	26
102	HOXB13 G84Eâ€“related Familial Prostate Cancers. American Journal of Surgical Pathology, 2014, 38, 615-626.	2.1	41
103	Expression of the p40 isoform of p63 has high specificity for cutaneous sarcomatoid squamous cell carcinoma. Journal of Cutaneous Pathology, 2014, 41, 831-838.	0.7	32
104	Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridizationâ€”a correlative study with urine PCA3 and TMPRSS2-ERG. Modern Pathology, 2014, 27, 609-620.	2.9	37
105	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nature Communications, 2014, 5, 4527.	5.8	129
106	Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. Prostate, 2014, 74, 983-990.	1.2	18
107	The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget, 2014, 5, 6654-6669.	0.8	82
108	Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. Journal of Clinical Oncology, 2014, 32, e16038-e16038.	0.8	1

#	Article	IF	Citations
109	Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. Journal of Clinical Oncology, 2014, 32, 5019-5019.	0.8	2
110	Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins. Endocrine, 2013, 44, 489-495.	1.1	29
111	Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. Translational Oncology, 2013, 6, 405-412.	1.7	13
112	Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. Molecular Cell, 2013, 49, 80-93.	4.5	130
113	HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab. Cancer Research, 2013, 73, 1635-1646.	0.4	213
114	Novel dual-color immunohistochemical methods for detecting ERGâ€“PTEN and ERGâ€“SPINK1 status in prostate carcinoma. Modern Pathology, 2013, 26, 835-848.	2.9	47
115	Usefulness of a Monoclonal ERG/FLI1 Antibody for Immunohistochemical Discrimination of Ewing Family Tumors. American Journal of Clinical Pathology, 2013, 139, 771-779.	0.4	34
116	Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3035-3040.	3.3	44
117	Abstract 5206: Role of CtBP1 as a transcriptional corepressor in prostate cancer.. , 2013, , .		1
118	Abstract 2564: Identification of a novel SPOP missense mutation from targeted next-generation sequencing of men with chromosome 17-q linkage.. , 2013, , .		0
119	Abstract 4188: The role of microRNA-101 as a master tumor suppressor in cancer.. , 2013, , .		0
120	Abstract 5348: Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.. , 2013, , .		0
121	Abstract 2780: Xenografts of human prostate cancer - a genetic profile analysis.. , 2013, , .		0
122	Abstract 4216: Novel RNAIn situhybridization method for the detection of ETV1, ETV4 and ETV5 rearrangements in prostate cancer.. , 2013, , .		0
123	Correlation of UrineTMPRSS2:ERGandPCA3to ERG+ and Total Prostate Cancer Burden. American Journal of Clinical Pathology, 2012, 138, 685-696.	0.4	72
124	Antibody-Based Detection of ERG Rearrangements in Prostate Core Biopsies, Including Diagnostically Challenging Cases: ERG Staining in Prostate Core Biopsies. Archives of Pathology and Laboratory Medicine, 2012, 136, 935-946.	1.2	88
125	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. Neoplasia, 2012, 14, 905-IN8.	2.3	59
126	Gene Fusions Associated with Recurrent Amplicons Represent a Class of Passenger Aberrations in Breast Cancer. Neoplasia, 2012, 14, 702-IN13.	2.3	60

#	Article	IF	Citations
127	The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012, 487, 239-243.	13.7	2,128
128	937 Concordance of ERG gene rearrangements and ERG protein expression in PIN lesions in prostate needle biopsies. European Urology Supplements, 2012, 11, e937-e937a.	0.1	0
129	Expressed Pseudogenes in the Transcriptional Landscape of Human Cancers. Cell, 2012, 149, 1622-1634.	13.5	250
130	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget, 2012, 3, 1011-1025.	0.8	126
131	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Medicine, 2011, 17, 1646-1651.	15.2	301
132	CD44-SLC1A2 Gene Fusions in Gastric Cancer. Science Translational Medicine, 2011, 3, 77ra30.	5.8	54
133	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature Biotechnology, 2011, 29, 742-749.	9.4	950
134	The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene, 2011, 30, 4339-4349.	2.6	95
135	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell, 2011, 19, 664-678.	7.7	397
136	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell, 2011, 20, 187-199.	7.7	191
137	Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis, 2011, 32, 1607-1614.	1.3	115
138	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Research, 2011, 21, 1028-1041.	2.4	166
139	Activation of NF-Î²B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Research, 2011, 71, 1325-1333.	0.4	71
140	Genomic Loss ofmiR-486Regulates Tumor Progression and theOLFM4Antiapoptotic Factor in Gastric Cancer. Clinical Cancer Research, 2011, 17, 2657-2667.	3.2	200
141	Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Science Translational Medicine, 2011, 3, 94ra72.	5.8	313
142	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery, 2011, 1, 35-43.	7.7	91
143	Abstract 2808: Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, , .		1
144	Abstract 4707: Discovery and characterization of PCAT-1, a novel lincRNA implicated in prostate cancer tumorigenesis. Cancer Research, 2011, 71, 4707-4707.	0.4	8

#	Article	IF	Citations
145	Cytogenetic Analysis and Related Techniques in Hematopathology. , 2011, , 81-94.		1
146	Abstract 2227: Concordance ofERGgene rearrangements andERGprotein expression in low grade PIN lesions in prostate needle biopsies. , 2011, , .		0
147	Abstract 2795: An onco-protein axis linking polycomb repressive complex 2 and polycomb repressive complex 1 through miRNAs in cancer. , 2011, , .		0
148	Abstract 2218: Integrated diagnostic methods for detection of multiple gene rearrangements in prostate cancer tissue specimens. , 2011, , .		0
149	Abstract 4840: DNA methylation patterns and transcript isoform regulation in prostate cancer. , 2011, , .		0
150	Abstract 929: Transcriptome sequencing identifies novel non-coding RNAs associated with prostate cancer progression. , 2011, , .		0
151	Abstract 2155: The origins and functional consequences of ETS gene fusions in prostate cancer. , 2011, , .		0
152	Abstract 953: Mechanistic rationale for inhibition of Poly(ADP-Ribose) Polymerase in ETS gene fusion positive prostate cancer. , 2011, , .		0
153	ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate. American Journal of Surgical Pathology, 2010, 34, 478-485.	2.1	91
154	The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene, 2010, 29, 5370-5380.	2.6	75
155	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine, 2010, 16, 793-798.	15.2	436
156	Chromosomal Aberrations in Solid Tumors. Progress in Molecular Biology and Translational Science, 2010, 95, 55-94.	0.9	26
157	Abstract 2214: An integrative approach to reveal driver gene fusions from paired end sequencing data in cancer. , 2010, , .		0
158	Abstract 3929: The role of chromosome architecture in the generation of gene fusions in prostate cancer. , 2010, , .		0
159	Abstract PR1: Genomic discovery ofCD44-SLC1A2gene fusions in gastric cancer. , 2010, , .		0
160	Inherent Signals in Sequencing-Based Chromatin-ImmunoPrecipitation Control Libraries. PLoS ONE, 2009, 4, e5241.	1.1	40
161	Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer. Science, 2009, 326, 1230-1230.	6.0	334
162	Chimeric transcript discovery by paired-end transcriptome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12353-12358.	3.3	302

#	Article	IF	Citations
163	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Modern Pathology, 2009, 22, 1083-1093.	2.9	209
164	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Modern Pathology, 2009, 22, 1176-1185.	2.9	91
165	Transcriptome sequencing to detect gene fusions in cancer. Nature, 2009, 458, 97-101.	13.7	791
166	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology, 2009, 27, 1005-1011.	9.4	69
167	Chromosomal Translocations in AML: Detection and Prognostic Significance. Cancer Treatment and Research, 2009, 145, 41-58.	0.2	7
168	RCP is a human breast cancerâ€“promoting gene with Ras-activating function. Journal of Clinical Investigation, 2009, 119, 2171-83.	3.9	107
169	Telomereâ€mediated genomic instability and the clinicoâ€pathological parameters in breast cancer. Genes Chromosomes and Cancer, 2008, 47, 1098-1109.	1.5	38
170	Chromosome classification using dynamic time warping. Pattern Recognition Letters, 2008, 29, 215-222.	2.6	45
171	Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Hepatology, 2008, 49, 52-60.	1.8	84
172	Automated Identification of Chromosome Segments Involved in Translocations by Combining Spectral Karyotyping and Banding Analysis. IEEE Transactions on Systems, Man and Cybernetics, Part A: Systems and Humans, 2008, 38, 1374-1384.	3.4	11
173	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. Science, 2008, 322, 1695-1699.	6.0	995
174	A Fluorescence In situ Hybridization Screen for E26 Transformationâ€“Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer. Cancer Research, 2008, 68, 7629-7637.	0.4	139
175	Abstract B90: Genomic loss of a microRNA leads to overexpression of EZH2 in cancer. , 2008, , .		0
176	Whole-Genome Cartography of Estrogen Receptor Î± Binding Sites. PLoS Genetics, 2007, 3, e87.	1.5	400
177	Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Research, 2007, 17, 828-838.	2.4	86
178	Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes Chromosomes and Cancer, 2007, 46, 288-301.	1.5	35
179	Derivation of Clinically Compliant MSCs from CD105+, CD24â^' Differentiated Human ESCs. Stem Cells, 2007, 25, 425-436.	1.4	303
180	Baculoviral Vector-Mediated Transient and Stable Transgene Expression in Human Embryonic Stem Cells. Stem Cells, 2007, 25, 1055-1061.	1.4	95

#	Article	IF	Citations
181	Genomic Amplification of the Human Telomerase Gene (TERC) in Pap Smears Predicts the Development of Cervical Cancer. American Journal of Pathology, 2005, 166, 1229-1238.	1.9	147
182	Whole-Genome Cartography of Estrogen ReceptorÎ± Binding Sites. PLoS Genetics, 2005, preprint, e87.	1.5	1
183	Deregulation of the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) gene in a B-cell chronic lymphocytic leukemia with a t(12;14)(q23;q32). Oncogene, 2004, 23, 6991-6996.	2.6	22
184	Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood, 2004, 103, 1862-1868.	0.6	96
185	Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clinical Endocrinology, 2003, 59, 180-189.	1.2	70
186	Clonal Chromosomal Defects in the Molecular Pathogenesis of Refractory Hyperparathyroidism of Uremia. Journal of the American Society of Nephrology: JASN, 2002, 13, 1490-1498.	3.0	49
187	BCL8 Is a Novel, Evolutionarily Conserved Human Gene Family Encoding Proteins with Presumptive Protein Kinase A Anchoring Function. Genomics, 2002, 80, 158-165.	1.3	17
188	Mutational Analyses of Connexin 26, Connexin 30 and Connexin 46 as Candidate Tumor Suppressor Genes in Parathyroid Carcinoma. International Journal on Disability and Human Development, 2002, 3, .	0.2	0
189	Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes and Cancer, 2002, 33, 114-122.	1.5	59
190	Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. Cancer Research, 2002, 62, 4089-94.	0.4	46
191	IRTA1 and IRTA2, Novel Immunoglobulin Superfamily Receptors Expressed in B Cells and Involved in Chromosome 1q21 Abnormalities in B Cell Malignancy. Immunity, 2001, 14, 277-289.	6.6	176
192	Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene, 2001, 20, 7686-7693.	2.6	37
193	MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood, 2000, 95, 2666-2671.	0.6	81
194	Vitamin D Receptor as a Candidate Tumor-Suppressor Gene in Severe Hyperparathyroidism of Uremia1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 868-872.	1.8	34
195	MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood, 2000, 95, 2666-2671.	0.6	3
196	Vitamin D Receptor as a Candidate Tumor-Suppressor Gene in Severe Hyperparathyroidism of Uremia. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 868-872.	1.8	30
197	MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood, 2000, 95, 2666-71.	0.6	24
198	A common molecular basis for rearrangement disorders on chromosome 22q11. Human Molecular Genetics, 1999, 8, 1157-1167.	1.4	385

#	Article	IF	Citations
199	Novel Chromosomal Abnormalities Identified by Comparative Genomic Hybridization in Parathyroid Adenomas1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1766-1770.	1.8	117
200	Novel Chromosomal Abnormalities Identified by Comparative Genomic Hybridization in Parathyroid Adenomas. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1766-1770.	1.8	93
201	Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Research, 1998, 58, 4260-3.	0.4	72
202	Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR 103. Tissue Antigens, 1997, 49, 564-573.	1.0	62
203	Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis.. Circulation Research, 1993, 73, 1000-1012.	2.0	326
204	Cornelia de Lange syndrome with ring chromosome 3.. Journal of Medical Genetics, 1990, 27, 405-406.	1.5	11